insulin-like growth factor binding protein-3 protease

calcium-dependent protease present in human pregnancy serum yielding IGF; inhibited by EDTA & phenanthroline; not present in baboon serum but may be present in rhesus monkey serum; however the protease splits this protein at a different site

Also Known As:

Networked: 29 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Flyvbjerg, Allan: 2 articles (12/2004 - 11/2004)
2.	Baxter, R C: 2 articles (12/2000 - 09/2000)
3.	Martin, J L: 2 articles (12/2000 - 09/2000)
4.	Salahifar, H: 2 articles (12/2000 - 09/2000)
5.	Brismar, K: 1 article (01/2008)
6.	Forsum, E: 1 article (01/2008)
7.	Lewitt, M: 1 article (01/2008)
8.	Lof, M: 1 article (01/2008)
9.	Olausson, H: 1 article (01/2008)
10.	Sohlstrom, A: 1 article (01/2008)

Related Diseases

1.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 07/01/1996 - "Increased IGFBP-3 protease activity has been shown in sera of children with IDDM as well as a decrease in this activity in response to insulin therapy. " 08/01/1995 - "Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus: a possible role for insulin in the regulation of IGFBP-3 protease activity." 08/01/1995 - "To characterize the relationship between insulin and IGFBP-3 protease activity, we have examined serum IGFBP-3 proteolysis in children with untreated insulin-dependent diabetes mellitus (IDDM) and have followed the effect of insulin therapy on serum IGFBP-3 proteolysis at 1 day, 1 week, and 1 month after the initiation of insulin therapy. " 09/01/1996 - "In seven subjects with IDDM, where serum IGFBP-1 and IGFBP-3 concentrations, and IGFBP-3 protease activity had also been measured in a previous study, the relationship between these variables and circulating free IGF-I concentrations were examined by linear regression analysis. " 08/01/1995 - "Molecular sizes of the IGFBP-3 proteolytic fragments (30 kDa, 24 kDa, and 19 kDa) and inhibition profile of IGFBP-3 protease were similar in IDDM and pregnancy sera, indicating that similar proteases (cation-dependent serine proteases) were active in both conditions. "
2.	Hypothyroidism 11/01/1994 - "Despite the marked reduction in circulating IGF levels and the generation of significant biochemical hypothyroidism, IGFBP-3 protease activity was not apparent during the 10-week period of the study.(ABSTRACT TRUNCATED AT 400 WORDS)"
3.	Breast Neoplasms (Breast Cancer) 11/01/2004 - "IGFBP-3 protease activity was not associated with breast cancer risk. " 12/01/2000 - "This suggests that the IGFBP-3 protease in MCF-7 cell medium can generate an inhibitor of IGF-dependent and independent breast cancer cell growth." 06/01/1999 - "IGFBP-3(Ad) showed no significant difference in its susceptibility to an IGFBP-3 protease present in medium conditioned by MCF-7 breast cancer cells compared to IGFBP-3(Pl), but appeared more resistant to the IGFBP-3 protease present in pregnancy serum. " 09/01/2000 - "Differential regulation of insulin-like growth factor-binding protein-3 protease activity in MCF-7 breast cancer cells by estrogen and transforming growth factor-beta1." 11/01/2004 - "We examined the association between IGF-I, IGF-II, IGF binding protein (IGFBP)-2, IGFBP-3, and IGFBP-3 protease activity and breast cancer risk in postmenopausal women, taking ER status of the breast cancer into consideration. "
4.	Neoplasms (Cancer) 11/01/1993 - "The IGFBP-3 protease activity in CSF was elevated in 15 of 16 (94%) patients with CNS tumors of high grade histological malignancy. " 07/01/1998 - "In addition, changes in IGFBP-3 protease activity because of cancer may contribute to alterations in IGF-I and -II, indicating the importance of measuring this parameter in addition to IGFs and IGFBPs when evaluating alterations in IGF-I." 06/01/1994 - "Insulin-like growth factor binding protein-3 concentrations and insulin-like growth factor binding protein-3 protease activity in sera of patients with malignant solid tumors or leukemia." 06/01/1994 - "Children with solid tumor or leukemia had significantly higher (p < 0.001) IGFBP-3 protease activity in serum than did normal controls or patients with sarcoma in complete remission. " 03/01/1999 - "To measure the serum concentrations of insulin-like growth factor I (IGF-I) and IGF binding protein 3 (IGFBP-3), and the level of IGFBP-3 protease activity in 38 children presenting with malignancies, and to assess their relation with auxological parameters and nutritional status. "
5.	Type 2 Diabetes Mellitus (MODY) 03/01/2000 - "In patients with noninsulin-dependent diabetes mellitus, urinary IGFBP-3 protease activity in micro- (n = 13) and macroalbuminuric patients (n = 12; mean +/- SD[SCAP], 75 +/- 25% and 84 +/- 24%) was significantly higher than that in normoalbuminuric patients (29 +/- 9%; P = 0.0001). " 05/01/1994 - "Neutral size-chromatography of sera demonstrated that IGFBP-3 protease activity in the approximately 130- to 150-kDa mol wt range is regulated by NIDDM and pregnancy in parallel with that of unfractionated sera.(ABSTRACT TRUNCATED AT 400 WORDS)" 06/01/1994 - "Despite the predominance of the 29 kDa IGFBP-3 fragment, we have previously demonstrated that the IGFBP-3 protease activity is not increased in fetal serum, in contrast to pregnancy or non-insulin dependent diabetes mellitus (NIDDM) sera.(ABSTRACT TRUNCATED AT 250 WORDS)"

Related Drugs and Biologics

1.	Insulin-Like Growth Factor I (IGF-1)
2.	Insulin-Like Growth Factor Binding Protein 3
3.	Insulin-Like Growth Factor Binding Protein 1
4.	Insulin-Like Growth Factor Binding Proteins
5.	Insulin-Like Peptides
6.	Insulin-Like Growth Factor II (Somatomedin A)
7.	Insulin (Novolin)
8.	Serine Proteases (Serine Protease)
9.	Transforming Growth Factor beta1 (TGF beta 1)
10.	Aromatase Inhibitors

Related Therapies and Procedures

1.	Therapeutics